Scott J Hultgren, 661068 Polo Downs Dr, Town And Country, MO 63017

6420127, Jul 16, 2002

Oct 10, 1996

08/640877

Scott Hultgren - Ballwin MO
Meta Kuehn - Berkeley CA
Zheng Xu - Blue Bell PA
Derek Ogg - Uppsala, SE
Mark Harris - Uppsala, SE
Matti Lepisto - Lund, SE
Charles Hal Jones - Saint Louis MO
Jan Kihlberg - Dalby, SE

Washington University - St. Louis MO
Siga Pharmaceuticals, Inc. - Corvallis OR

G01N 33569

435 737, 4242411, 4242421, 4242571, 435849

Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

6495539, Dec 17, 2002

Feb 19, 1999

09/252792

Scott J. Hultgren - Ballwin MO
Fredrik Almqvist - Umea, SE
Gabriel Soto - Chesterfield MO

Washington University - St. Louis MO

C07D50100

514192, 514194, 514195, 514197, 540205, 540301, 540302, 540310, 540347, 540215, 548201, 436547, 435DIG 34, 435DIG 49

Compounds of the formula and the salts, esters and amides thereof wherein Z is S, SO, SO or O; each of R , R and R is independently H or substituted or unsubstituted alkyl (1-10C), substituted or unsubstituted alkenyl, substituted or unsubstituted acyl (2-11C), substituted or unsubstituted aryl (6-14C), substituted or unsubstituted arylcarbonyl (7-15C), substituted or unsubstituted arylalkyl (7-15C), substituted or unsubstituted pyridyl wherein substituents on any alkyl, alkenyl, or acyl moiety are selected from the group consisting of halo, and RO, wherein R is H or alkyl (1-6C), and substituents on any aryl or pyridyl moiety are selected from the group consisting of halo, and RO, where R is H or alkyl (1-6C), âCN and âCF ; with the proviso that R is not H and R and R are not identical and with the proviso that in formula (1), the B ring may contain one double bond that is located between positions 2 and 3, and in formula (2), the B ring may contain one double bond that can be located between positions 2 and 3 or positions 3 and 4 are useful as antibacterial agents.

6500434, Dec 31, 2002

Apr 23, 1999

09/298494

Solomon Langermann - Baltimore MD
Scott J. Hultgren - Ballwin MO
Jerome S. Pinkner - St. Louis MO
Christine Gale Auguste - Germantown MD

MedImmune, Inc. - Gaithersburg MD

A61K 39385

42419711, 4241841, 4241921, 4241931, 4242341, 4242421, 4242571, 4242001, 4242031, 4242411, 530402

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with heteropolymeric protein complexes as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A novel vector for expressing the FimC-H complex at optimal levels is also disclosed.

6548265, Apr 15, 2003

Mar 7, 2001

09/799576

Scott Hultgren - Ballwin MO
Meta Kuehn - Berkeley CA
Zheng Xu - Blue Bell PA
Derek Ogg - Uppsala, SE
Mark Harris - Uppsala, SE
Matti Lepisto - Lund, SE
Charles Hal Jones - Saint Louis MO
Jan Kihlberg - Dalby, SE

Washington University - St. Louis MO
Siga Pharmaceuticals, Inc. - Corvallis OR

G01N 33569

435 737, 4241841, 4242341, 4242421, 4242572, 4242411, 435 732, 435243, 4352528

Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

6596504, Jul 22, 2003

Mar 7, 2001

09/799540

Scott Hultgren - Ballwin MO
Meta Kuehn - Berkeley CA
Zheng Xu - Blue Bell PA
Derek Ogg - Uppsala, SE
Mark Harris - Uppsala, SE
Matti Lepisto - Lund, SE
Charles Hal Jones - Saint Louis MO
Jan Kihlberg - Dalby, SE

Washington University - St. Louis MO
SIGA Pharmaceuticals, Inc. - New York NY

A61K 3902

435 732, 424 91, 424 92, 4241301, 4241641, 4241841, 4241851, 4242341, 4242411, 4242781, 43525223, 436501, 530300, 530350

Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

6872542, Mar 29, 2005

Mar 7, 2001

09/799584

Scott Hultgren - Ballwin MO, US
Meta Kuehn - Berkeley CA, US
Zheng Xu - Blue Bell PA, US
Derek Ogg - Uppsala, SE
Mark Harris - Uppsala, SE
Matti Lepisto - Lund, SE
Charles Hal Jones - Saint Louis MO, US
Jan Kihlberg - Dalby, SE

SIGA Pharmaceuticals, Inc. - New York NY
Washington University - St. Louis MO

G01N033/554
A61K049/00
A61K039/395
A61K039/40
A61K039/38

435 732, 424 91, 424 92, 4241301, 4241641, 4241841, 4241851, 4242341, 4242411, 4242781, 43525233, 436501, 530300, 530350

Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

6913750, Jul 5, 2005

Dec 28, 2001

10/027350

Scott J. Hultgren - Town and Country MO, US
Solomon Langermann - Baltimore MD, US
Frederic G. Sauer - St. Louis MO, US

MedImmune, Inc. - Gaithersburg MD
Washington University - St. Louis MO

A61K039/02
A01N063/00
A01N065/00
G01N033/554
C12P021/06

4241901, 424 931, 435 732, 435 691

A protein construct comprising a pilus protein portion, preferably a structurally stabilized pilus-protein, and an additional, or effector, portion other than a pilus protein or chaperone and wherein said effector portion serves to stabilize the pilus protein portion and to confer a therapeutic activity, such as vaccine activity or anti-microbial or anticancer activity, on the protein construct is disclosed. Such effector portion commonly comprises a donor strand complementary segment capable of structurally stabilizing a pilus protein subunit and attaching the auxiliary portion to said subunit to form the pilus protein analog of the invention. Methods of using said protein constructs are also disclosed as well as the formation and use of analogs comprising fragments of a pilus protein linked to effector components to produce immunogenic and/or therapeutic activity.

6962791, Nov 8, 2005

Mar 7, 2001

09/799608

Scott Hultgren - Ballwin MO, US
Meta Kuehn - Berkeley CA, US
Zheng Xu - Blue Bell PA, US
Derek Ogg - Uppsala, SE
Mark Harris - Uppsala, SE
Matti Lepisto - Lund, SE
Charles Hal Jones - Saint Louis MO, US
Jan Kihlberg - Dalby, SE

Washington University - St. Louis MO
Siga Pharmaceuticals, Inc. - New York NY

G01N033/569
A61K039/108
A61K039/02

435 737, 4242411, 4242422, 4242571, 435849

Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.